胰腺癌筛查与早期发现:现状与进展
本文综述胰腺癌筛查现状,指出总体5年生存率约13%,预后差主要源于晚期诊断。高危人群(家族史、易感基因、遗传综合征、癌前病变)适合筛查,推荐超声内镜、MRI和CT作为主要影像手段。人工智能增强影像和新型血清生物标志物有望提高早期检出率,但尚缺乏经过验证的、经济高效的筛查工具。
要点
- 胰腺癌总体5年生存率约13%,早期无症状是预后差的主要原因。
- 高危人群(家族史、易感基因、遗传综合征、癌前病变)应考虑筛查。
- 超声内镜、MRI和CT是推荐的主要筛查影像手段。
核心结论
- 胰腺癌筛查在高危人群中具有早期发现和改善生存的潜力,但缺乏经过验证的、经济高效且可推广的筛查工具。
- AI增强影像与新型血清生物标志物是改善早期胰腺癌检出的有前景方向。
研究设计与样本
- 本文为综述,旨在批判性评估当前筛查策略、影像与生物标志物新兴技术及其转化潜力。
- 文中提及影像证据支持超声内镜、MRI和CT作为主要影像模式用于早期发现。
关键影像表现/征象
- 常规影像在胰腺癌诊断和分期中起关键作用,但常常无法显示视觉上隐匿的病灶。
- AI增强影像有潜力在确诊前的CT和MRI上改善早期胰腺癌检出。
诊断标准与关键数值
- 高危个体定义为具有胰腺癌家族史、易感基因、某些遗传综合征或癌前病变的患者。
- 高危个体与癌前病变患者的筛查间期和影像策略有所不同。
- 新型血清生物标志物具有更高敏感度和特异度,为非侵入性筛查提供有前景的途径。
临床应用与阅片要点
- 放射科医生应将超声内镜、MRI和CT作为胰腺癌高危人群筛查的主要影像工具。
- 阅片时需警惕常规影像容易漏诊的隐匿性病变,并结合临床高危因素。
- 关注AI辅助检测工具在胰腺癌早期征象识别中的应用价值。
局限性
- 尚缺乏经过验证的、经济高效且可推广的胰腺癌筛查工具。
- 原文总体5年生存率约13%,未报告具体人群或时限的细分数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Pancreatic cancer remains one of the most lethal malignancies, with an overall 5-year survival rate of approximately 13%. The poor prognosis is primarily due to late-stage diagnosis, as early-stage disease is often asymptomatic. Screening for pancreatic cancer in high-risk individuals offers the potential for early detection, timely intervention, and improved survival outcomes. Individuals at elevated risk for pancreatic cancer-that is, those with a family history or predisposing genes for pancreatic cancer or certain inherited syndromes and patients with precursor lesions or precancerous lesions-are considered suitable candidates for screening. Imaging is recognized as an important tool for diagnosis and staging of pancreatic cancer. Evidence supports use of endoscopic US, MRI, and CT as primary imaging modalities to facilitate early detection. Screening intervals and imaging strategies vary in high-risk individuals and those with precursor or precancerous lesions. While conventional imaging plays a key role in diagnosis and staging, it often fails to allow detection of visually occult disease, an area where artificial intelligence-enhanced imaging offers potential. These advancements have the potential to improve detection of early pancreatic cancer with prediagnostic CT and MRI. In parallel, the development of novel serum biomarkers with greater sensitivity and specificity provides promising avenues for noninvasive screening. Despite these advances, there remains a critical unmet need for validated, cost-effective, and scalable tools. The authors aim to critically appraise current screening strategies, highlight emerging technologies in imaging and biomarkers, and discuss their potential to transform early detection and improve clinical outcomes in high-risk populations. © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license See the invited commentary by Luk and Flusberg in this issue.
引用
- Srinivas Rao, Ghosh, Goenka, et al. Pancreatic Cancer Screening and Early Detection: Where Are We Now? Radiographics. 2026. PMID: 42752241. doi:10.1148/rg.250146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。